Profile: Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines. Our primary areas of focus include HIV/AIDS, liver disease, serious cardiovascular and respiratory conditions. Our portfolio of 12 marketed products includes a number of category firsts and market leaders, including Atripla®, & Viread®. Our Atripla® is the first single-tablet regimen for HIV infection. Our Viread® is used for the treatment of chronic hepatitis B, a serious liver disease caused by the hepatitis B virus.

The company has revenues of USD 1-5 Million, has ~200 employees.